Zai Lab Ltd. Unsponsored ADR Stock

$32.63

1.09% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Zai Lab Ltd. Unsponsored ADR Stock price

$32.63

-39.41 54.71% 5Y

Nasdaq, Closing price Tue, May 20 2025

-0.36 1.09%

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$3.58b
Enterprise Value	$2.92b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	6.98
P/S ratio (TTM) P/S ratio	8.57
P/B ratio (TTM) P/B ratio	4.36
Revenue growth (TTM) Revenue growth	43.72%
Revenue (TTM) Revenue	$418.33m
EBIT (operating result TTM) EBIT	$-268.12m
Free Cash Flow (TTM) Free Cash Flow	$-192.68m
Cash position	$857.26m
EPS (TTM) EPS	$-2.50
P/E forward	negative
P/S forward	6.34
EV/Sales forward	5.16
Short interest	6.89%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Zai Lab Ltd. Unsponsored ADR Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

15x Buy

88%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

Buy

88%

Hold

12%

Analyst Estimates with Stock Price Targets

Financial data from Zai Lab Ltd. Unsponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	418 418	44% 44% 100%
- Direct Costs	153 153	41% 41% 37%
Gross Profit	265 265	45% 45% 63%
- Selling and Administrative Expenses	272 272	0% 0% 65%
- Research and Development Expense	241 241	12% 12% 58%
EBITDA	-247 -247	31% 31% -59%
- Depreciation and Amortization	21 21	20% 20% 5%
EBIT (Operating Income) EBIT	-268 -268	29% 29% -64%
Net Profit	-252 -252	26% 26% -60%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Zai Lab Ltd. Unsponsored ADR Stock News

Neutral

Business Wire

●

one day ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company's potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated i...

Neutral

Seeking Alpha

●

10 days ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Jonathan W...

Neutral

Business Wire

●

13 days ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2025, along with recent product highlights and corporate updates. “In the first quarter, we continued to advance both our global pipeline and commercial business,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are rapidly expan...

More Zai Lab Ltd. Unsponsored ADR News

Company Profile

Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Head office	Cayman Islands
CEO	Ying Du
Employees	1,869
Founded	2014
Website	www.zailaboratory.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now